2 Top Healthcare Stocks Ready for a Bull Run

Pfizer (NYSE: PFE) has (at least) two major revenue drivers that could power its share price higher: Its coronavirus vaccine, Comirnaty, and its new antiviral treatment for COVID-19, Paxlovid. Comirnaty is responsible for a sizable portion of its trailing revenue of $69.3 billion, and it's doubtlessly why the pharma's quarterly sales have grown by 134.4% as of Q3 in 2021. Pfizer also plans to invest more in the mRNA technology behind Comirnaty to build out its pipeline of vaccines and therapeutics.